SCHEMBL25795344

SCHEMBL25795344

Cc1ncc2c(cnn2C2CCCCO2)c1Br

nearest known ligand 0.41

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ CYP4F2 P78329 2/20 0.41
▸ CYP4A11 Q02928 2/20 0.41
▸ ALDH1A1 P00352 1/20 0.39
▸ LMNA P02545 1/20 0.39
▸ POLB P06746 1/20 0.39
▸ RXRA P19793 1/20 0.39
▸ RXRB P28702 1/20 0.39
▸ RXRG P48443 1/20 0.39
▸ GAA P10253 1/20 0.36
▸ PDE1A P54750 2/20 0.35
▸ PDE1B Q01064 2/20 0.35
▸ PDE1C Q14123 2/20 0.35
▸ CYP2C19 P33261 1/20 0.35
▸ ATR Q13535 8/20 0.35
▸ RET P07949 2/20 0.34
▸ PDE9A O76083 1/20 0.33
▸ YTHDC1 Q96MU7 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25795329 0.84 RXRA (0.46) CYP4F2CYP4A11ALDH1A1LMNAPOLB
SCHEMBL21195793 0.83 CYP4F2 (0.45) CYP4F2CYP4A11ALDH1A1LMNAPOLB
SCHEMBL19948345 0.82 CYP4F2 (0.44) CYP4F2CYP4A11ALDH1A1LMNAPOLB
SCHEMBL19637212 0.82 CYP4F2 (0.44) CYP4F2CYP4A11ALDH1A1LMNAPOLB
SCHEMBL25795343 0.81 CYP4F2 (0.42) CYP4F2CYP4A11ALDH1A1LMNAPOLB
SCHEMBL24536348 0.81 ALDH1A1 (0.44) CYP4F2CYP4A11ALDH1A1LMNAPOLB
SCHEMBL1709840 0.81 CYP4F2 (0.45) CYP4F2CYP4A11ALDH1A1LMNAPOLB
SCHEMBL21379219 0.80 CYP4F2 (0.45) CYP4F2CYP4A11ALDH1A1LMNAPOLB
SCHEMBL21196104 0.80 CYP4F2 (0.42) CYP4F2CYP4A11ALDH1A1LMNAPOLB
SCHEMBL21196016 0.80 CYP4F2 (0.40) CYP4F2CYP4A11ALDH1A1LMNAPOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230219956-A1 QUINAZOLINE COMPOUND AND PHARMACEUTICAL APPLICATION THEREOF BETTA PHARMACEUTICALS CO.,LTD (CN) 2023-07-13 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230219956-A1 QUINAZOLINE COMPOUND AND PHARMACEUTICAL APPLICATION THEREOF H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, ABCG2, NQO2 CYP4F2 606/4885CYP4A11 836/4885ALDH1A1 2410/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback